1340-P: The Association of SGLT2i vs. DPP4i on Fracture—Cohort Study of Veterans with Diabetes
Abstract
Objective: Increased bone turnover is associated with SGLT2i use. Patients with diabetes have adverse effects on bone metabolism. Our aim was to evaluate if SGLT2i was associated with fractures versus DPP4i.
Methods: A retrospective cohort combined Veterans Administration, Medicare, and National Death Index databases. New users of SGLT2i with diabetes (87% empagliflozin; 10.2% canagliflozin; 2.6% dapagliflozin) or DPP4i (51% saxagliptin; 30% sitagliptin; 12% alogliptin) were followed from the prescription fill until a fracture event, death or study end. Fractures included: face/skull, spine, ribs, long bones, hand/feet/ digits, or hip. Fractures were identified based on a validated algorithm with PPV 91.3% (86.8, 94.4) compared to medical records. Cox models compared fractures between SGLT2i and DPP4i in a propensity score weighted cohort adjusted for clinical and lab data including vitamin D levels, smoking, and medications.
Results: The weighted cohort included 36253 SGLT2i vs 36189 DPP4i episodes. Median age was 69 years and diabetes duration 9.3 (5.7, 13.7) years. In matched weighted analyses, there were 468 and 549 fractures among SGLT2i and DPP4i users, respectively. There were no clinical differences in fractures per 1000 person years: 18.1 (16.6, 19.7) vs. 20.2 (19.1, 21.4) [aHR 0.89 (0.80, 0.99)].
Conclusions: SGLT2i use for diabetes was not associated with increased fracture outcomes compared to DPP4i
K.D. Snyder: None. A.J. Hackstadt: None. K.E. Griffin: None.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.